AMRI's days of posting quarterly net losses appear to be far behind, as the company rode an 11% revenue jump to $6.5 million in net income, up from a negative $3.8 million in the same period last year.
When Sanofi bought an 80% stake in Indian vaccinemaker Shantha Biotech in 2009, the talk was of the deal accelerating growth in emerging markets.Things played out a little differently though.
AMRI has locked down another 5-year partnership with Japan's Ono Pharmaceutical, agreeing to provide development and manufacturing services for the company's treatments, which include a promising multiple sclerosis drug.
Citing a boom in demand for biologics, Catalent has cut the ribbon on a new biomanufacturing facility in Madison, WI, a plant the company says will quadruple its capacity.
The spread of H7N9 in China is a reminder of why the Department of Health and Human Services (HHS) gave Novartis $487 million to build its cell culture vaccine production plant. If H7N9 reaches the U.S., the country will be better prepared because of the investment.
Two big-time drugmakers are having to put their plans on hold thanks to problems with contract manufacturers, with GlaxoSmithKline facing a prolonged drug shortage and Allergan enduring an FDA rejection.
Swiss drugmaker Debiopharma has teamed up with India's Shasun Pharmaceuticals, striking a deal with the CMO to manufacture Huperzine-A, a drug designed to improve cognitive performance in patients with Alzheimer's disease.
As more and more drugmakers eye antibody-drug conjugate development as a path to blockbusters, Catalent has licensed ADC technology from Redwood Bioscience, planning to roll the offering into its service platform.
U.S. CRO Frontage has received a Form 483 from the FDA after an inspection of its bioanalytical lab in Shanghai.
France's Sanofi is expanding its contract manufacturing capabilities, teaming up with Transgene to spend $13 million on a new CMO platform.